Alps Advisors Inc. increased its position in Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) by 4.7% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 21,090 shares of the company’s stock after buying an additional 939 shares during the period. Alps Advisors Inc. owned 0.09% of Aquinox Pharmaceuticals worth $297,000 at the end of the most recent reporting period.

Separately, Investment Centers of America Inc. bought a new position in shares of Aquinox Pharmaceuticals during the first quarter worth approximately $172,000. Hedge funds and other institutional investors own 95.15% of the company’s stock.

Aquinox Pharmaceuticals, Inc. (NASDAQ AQXP) opened at 14.66 on Wednesday. Aquinox Pharmaceuticals, Inc. has a 52-week low of $9.23 and a 52-week high of $19.97. The firm has a 50-day moving average price of $14.46 and a 200-day moving average price of $15.18. The company’s market cap is $343.98 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.59). On average, analysts forecast that Aquinox Pharmaceuticals, Inc. will post ($2.15) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at

A number of research analysts recently commented on the company. Zacks Investment Research upgraded Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research report on Thursday, August 10th. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 8th. BidaskClub upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. ValuEngine upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Cantor Fitzgerald set a $28.00 target price on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, May 9th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Aquinox Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $22.25.

In related news, insider David Main sold 15,625 shares of the business’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $13.26, for a total value of $207,187.50. Following the sale, the insider now directly owns 77,530 shares in the company, valued at $1,028,047.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.70% of the stock is currently owned by insiders.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Want to see what other hedge funds are holding AQXP? Visit to get the latest 13F filings and insider trades for Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP).

Institutional Ownership by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.